Pharmaceutical Approval Update.
Pharmaceutical Approval Update.
P T. 2017 Oct;42(10):620-621
Authors: Kaufman MB
Abstract
L-glutamine oral powder (Endari) for reducing the acute complications of sickle cell disease; edaravone (Radicava) for the treatment of amyotrophic lateral sclerosis; and midostaurin (Rydapt) for the treatment of acute myeloid leukemia in combination with chemotherapy.
PMID: 29018296 [PubMed]
Source: P and T - Category: Drugs & Pharmacology Tags: P T Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | ALS | Chemotherapy | Drugs & Pharmacology | Leukemia | Sickle Cell Anemia